Pneumococcal Vaccine Market Report, Industry Overview, Growth Rate and Forecast 2026

11/gen/2021 20:11:35 IMARC Group Contatta l'autore

According to the IMARC Group: the pneumococcal vaccine helps in protecting both children and adults against pneumococcal infections. Pneumococcal infections are caused by Streptococcus pneumoniae or pneumococcus bacteria, which can cause severe lung infection (pneumonia), blood infection (bacteremia), and infection in the lining of the brain and spinal cord (meningitis). Children in the age group of 2-5 years and geriatric individuals are the most at-risk population for pneumococcal infections. The pneumococcal vaccine stimulates the immune system and prevents the spread of infection, thereby eliminating the need for hospitalization and reducing the fatality rate.

Request for a free sample copy of this report:

The rising parental concerns towards the high prevalence of pneumococcal infection in infants are propelling the demand for pneumococcal vaccines. Furthermore, the growing geriatric population who are more prone to chronic respiratory diseases is also augmenting the market growth. Additionally, the increasing consumption of cigarettes, snugs, cigars, hookah, etc., has further led to the rising incidences of severe lung diseases, thereby driving the global market. Additionally, the emergence of the Pneumococcal Conjugate Vaccine (PCV) for immunizing infants will continue to bolster the market growth in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global pneumococcal vaccine market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, vaccine type, product type, distribution channel and end user.

Explore full report with table of contents:

Breakup by Vaccine Type:

  • Pneumococcal Conjugate Vaccine
  • Pneumococcal Polysaccharide Vaccine

Breakup by Product Type:

  • Prevnar 13
  • Synflorix
  • Pneumovax 23

Breakup by Distribution Channel:

  • Distribution Partner Companies
  • Non-Governmental Organizations (NGO)
  • Government Authorities

Breakup by End User:

  • Pediatrics
  • Adults

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., GlaxoSmithKline Plc., Merck & Co. Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt Ltd and Walvax Biotechnology Co. Ltd.

Browse Related Report

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US:
30 N Gould St, Ste R
Sheridan, WY 82801, USA
USA: +1-631-791-1145
Follow us on twitter: @imarcglobal

blog comments powered by Disqus è un servizio offerto da Factotum Srl